Teva Pharmaceutical Industries and Lonza Group have decided to discontinue their biosimilars collaboration following a strategic review of the Teva-Lonza Joint Venture (TL-JV). The TL-JV began in 2009; the move will allow both companies to pursue their own strategies based on the investments and progress that the joint venture has made thus far.    Dr. Michael Hayden, president, Global R&D and chief scientific officer of Teva, said, “Teva has a track record of success in the biologics arena ...